Are Glycopeptides Still Appropriate and Convenient for Empiric Use?

References

• Deresinski S. Counterpoint: Vancomycin and Staphylo-coccus aureus - an antibiotic enters obsolescence. Clin Infect Dis, 2007; 44 (12): 1543–8.
   PubMed Web of Science ®Google Scholar
• Uckay I, Harbarth S, Pittet D. Management of Gram-pos-itive bacteraemia. Curr Opin Infect Dis, 2007; 20 (6): 561–7.
   PubMed Web of Science ®Google Scholar
• Grundmann H, Aires-de-Sousa M, Boyce J, et al. Emer-gence and resurgence of meticillin-resistant Staphylococcus au-reus as a public-health threat. Lancet, 2006; 368 (9538): 874–85.
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J, et al. Invasive methi-cillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298 (15): 1763–71.
   PubMed Web of Science ®Google Scholar
• Lewis JS 2, Ellis MW. Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased sus-ceptibility to vancomycin: clinical significance and options for management. Curr Opin Infect Dis, 2007; 20 (6): 568–73.
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infec-tions: efficacy and toxicity. Arch Intern Med, 2006; 166 (19): 2138–44.
   PubMedGoogle Scholar
• Soriano A., Marco F, Martinez JA, et al. Influence of van-comycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin In-fect Dis, 2008; 46 (2): 193–200.
   PubMed Web of Science ®Google Scholar
• Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcus faecium in-fection or colonization in 145 matched case patients and control patients. Clin Infect Dis, 1996; 23 (4): 767–72.
   PubMed Web of Science ®Google Scholar
• Sakka V, Tsiodras S, Galani L, et al. Risk-factors and pre-dictors of mortality in patients colonised with vancomycin-resis-tant enterococci. Clin Microbiol Infect, 2008; 14 (1): 14–21.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human Staphylo-coccal clinical isolates recovered in the United States. Antimicrob Agents Chemother, 2008; 52 (6): 2244–6.
   PubMed Web of Science ®Google Scholar
• Cookson BD, Macrae MB, Barrett SP, et al. Guidelines for the control of glycopeptide-resistant enterococci in hospitals. J Hosp Infect, 2006; 62 (1): 6–21.
   PubMed Web of Science ®Google Scholar
• 2006 Annual Report. 2007, EARSS Management Team: Bilthoven, The Netherlands.
   Google Scholar
• Go11 C, Balmer P, Schwab F, et al. Different Trends of MRSA and VRE in a German Hospital, 1999-2005. Infection, 2007; 35 (4): 245-9.
   Google Scholar
• Humphreys, H. Implementing guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: how valid are international comparisons of success? J Hosp Infect, 2006; 62 (2): 133–5.
   PubMed Web of Science ®Google Scholar
• Hsu LY, Wijaya L, Tan BH. Management of healthcare-associated methicillin-resistant Staphylococcus aureus. Expert Rev Anti Infect Ther, 2005; 3 (6): 893–905.
   PubMedGoogle Scholar
• Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylo-coccus aureus (MRSA) infections in the UK. J Antimicrob Chemother, 2006; 57 (4): 589–608.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tis-sue infections. Clin Infect Dis, 2005; 41 (10): 1373–406.
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, de Pauw BE. Microbiologic consequences of new approaches to managing hematologic ma-lignancies. Rev Clin Exp Hematol, 2005; 9 (2): E2.
   PubMedGoogle Scholar
• Rose WE, Rybak MJ, Tsuji BT, et al. Correlation of van-comycin and daptomycin susceptibility in Staphylococcus au-reus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother, 2007; 59 (6): 1190–3.
   PubMed Web of Science ®Google Scholar
• Cui L, Ma X, Sato K, et al. Cell wall thickening is a com-mon feature of vancomycin resistance in Staphylococcus au-reus. J Clin Microbiol, 2003; 41 (1): 5–14.
   PubMed Web of Science ®Google Scholar
• Selton-Suty C, Duval X, Brochet E, et al. [New French rec-ommendations for the prophylaxis of infectious endocarditis]. Arch Mal Coeur Vaiss, 2004; 97 (6):. 626–31.
   PubMedGoogle Scholar
• Baddour LM, Wilson WR, Bayer AS, et al. Infective en-docarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Dis-ease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Sur-gery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation, 2005; 111 (23): e394–434.
   Web of Science ®Google Scholar
• Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection, 2005; 33(5-6): 309–13.
   PubMed Web of Science ®Google Scholar
• German guidelines for the diagnosis and management of infective endocarditis. Int J Antimicrob Agents, 2007; 29 (6): 643-57.
   Google Scholar
• Westling K, Aufwerber E, Ekdahl C, et al. Swedish guide-lines for diagnosis and treatment of infective endocarditis. Scand J Infect Dis, 2007; 39 (11): 929–46.
   PubMedGoogle Scholar
• Cunha BA, Mickail N, Eisenstein L. E. faecalis van-comycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung, 2007; 36 (6): 456-61.
   Google Scholar
• Ramsdale DR, Turner-Stokes L. Prophylaxis and treat-ment of infective endocarditis in adults: a concise guide. Clin Med, 2004; 4 (6): 545–50.
   Web of Science ®Google Scholar
• Davis SL, McKinnon PS, Hall LM, et al. Daptomycin ver-sus vancomycin for complicated skin and skin structure infec-tions: clinical and economic outcomes. Pharmacotherapy, 2007; 27 (12): 1611–8.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. An-timicrobial prophylaxis against infective endocarditis 2008 17 March 2008; Available from: http://www.nice.org.uk/guid-ance/index.jsp?action=byID&o=11938. Accessed April 1, 2008.
   Google Scholar
• Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med, 1988; 109 (8): 619–24.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 2006; 355 (7): 653–65.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing line-zolid with vancomycin. Intensive Care Med, 2004; 30 (3): 388–94.
   PubMed Web of Science ®Google Scholar
• Vinh DC, Embil JM. Rapidly progressive soft tissue infec-tions. Lancet Infect Dis, 2005; 5 (8): 501–13.
   PubMed Web of Science ®Google Scholar
• Rao KV, Correll TA. Evaluation of alterations of pro-thrombin time with the use of daptomycin. In: Abstracts of the Forty-fourth IDSA Annual Meeting. Toronto, Ontario, Canada: Alexandria, VA, USA. 2006. Abstract 218 p85.
   Google Scholar
• Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious Gram-positive infections. Expert Opin Investig Drugs, 2007; 16 (3): 347–57.
   PubMed Web of Science ®Google Scholar
• Akins RL, Haase KK. Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacother-apy, 2005; 25 (7): 1001–10.
   PubMed Web of Science ®Google Scholar
• Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of methicillin-resistant Staphylococ-cus aureus (MRSA) in healthcare facilities. J Hosp Infect, 2006; 63 Suppl 1: S1–44.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Van Laethem Y, Courvalin P, et al. Gly-copeptide antibiotics: from conventional molecules to new de-rivatives. Drugs, 2004; 64 (9): 913–36.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, et al. In vitro ac-tivities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother, 2000; 44 (4): 1062–6.
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro bactericidal ac-tivity of daptomycin against staphylococci. J Antimicrob Chemother, 2002; 49 (3): 467–70.
   PubMed Web of Science ®Google Scholar
• Smith PF, Booker BM, Ogundele AB, et al. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dal-fopristin against Gram-positive bacterial isolates from a large can-cer center. Diagn Microbiol Infect Dis, 2005; 52 (3): 255–9.
   PubMed Web of Science ®Google Scholar
• Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphy-lococcus aureus cells. Antimicrob Agents Chemother, 2007; 51 (12): 4255–60.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Nathwani D, Burton P, et al. Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). Int J Antimicrob Agents, 2007; 29 (6): 693–9.
   PubMed Web of Science ®Google Scholar
• Matthews PC, Taylor A, Byren I, et al. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect, 2007; 55 (5): 408–13.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Sabbatani S, Chiodo F. Severe staphylococ-cal knee arthritis responding favourably to linezolid, after gly-copeptide-rifampicin failure: a case report and literature review. Scand J Infect Dis, 2005; 37(6-7): 513–7.
   PubMed Web of Science ®Google Scholar
• Zinkernagel AS, Speck RF, Ruef C, et al. Rapidly de-structive Staphylococcus epidermidis endocarditis. Infection, 2005; 33 (3): 148–50.
   PubMed Web of Science ®Google Scholar
• Kent and Medway Cancer Network. Managing neutrope-nia. 2006.
   Google Scholar
• BNF. No 54 September Editor D.K. Mehta. 2007. 944.
   Google Scholar
• Martone WJ, Lamp KC. Efficacy of daptomycin in com-plicated skin and skin-structure infections due to methicillin-sen-sitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin, 2006; 22 (12): 2337–43.
   PubMed Web of Science ®Google Scholar
• Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs, 2007; 67 (10): 1483–512.
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Corey GR. Daptomycin: a rapidly bacterici-dal lipopeptide for the treatment of Gram-positive infections. Ex-pert Rev Anti Infect Ther, 2007; 5 (2): 177–84.
   PubMed Web of Science ®Google Scholar
• Kollef M, Sherman G, Ward S, et al. Inadequate antimi-crobial treatment of infections. A risk factor for hospital mortal-ity among critically ill patients. Chest, 1999; 115: 462–474.
   Google Scholar
• Elliott TS, Foweraker J, Gould FK, et al. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Work-ing Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother, 2004; 54 (6): 971–81.
   PubMed Web of Science ®Google Scholar
• Bodmann KF. Current guidelines for the treatment of se-vere pneumonia and sepsis. Chemotherapy, 2005; 51 (5): 227–33.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Grau S, Garcia-Arnillas MP. Gram-pos-itive cocci infections in intensive care: guide to antibacterial se-lection. Drugs, 2006; 66 (6): 751–68.
   PubMed Web of Science ®Google Scholar
• Peset V, Tallon P, Sola C, et al. Epidemiological, micro-biological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis, 2000; 19 (10): 742–9.
   PubMed Web of Science ®Google Scholar
• Cui L, Tominaga E, Neoh HM, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother, 2006; 50 (3): 1079–82.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. Heart Lung, 2006; 35 (3): 207–11.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Hamid N, Kessler H, et al. Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphy-lococcus aureus (MSSA) tricuspid valve acute bacterial endo-carditis from a peripherally inserted central catheter (PICC) line. Heart Lung, 2005; 34 (6): 442–7.
   PubMed Web of Science ®Google Scholar
• Fossaceca C. Outcomes analysis of daptomycin use in a community hospital. Adv Ther, 2007; 24 (3): 517–28.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis, 2004; 38 (12): 1673–81.
   PubMed Web of Science ®Google Scholar
• Krige JE, Lindfield K, Friedrich L, et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin, 2007; 23 (9): 2147–56.
   PubMed Web of Science ®Google Scholar
• Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis ex-ecutive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J, 2004; 25 (3): 267–76.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2004; 39 (7): 885–910.
   PubMed Web of Science ®Google Scholar
• Mathews CJ, Kingsley G, Field M, et al. Management of septic arthritis: a systematic review. Ann Rheum Dis, 2007; 66 (4): 440–5.
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rjinehart E, Jackson M, et al. Management of multi-drug resistant organisms in 2006. 2006; Available from: http://www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline200 6.pdf. Accessed 19 November 2007.
   Google Scholar
• Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin Micro-biol Infect, 2007; 13 (4): 351–3.
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Sader HS, et al. Spectrum and po-tency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis, 2006; 54 (2): 149–53.
   PubMed Web of Science ®Google Scholar
• Prevalence of methicillin-resistant Staphylococcus aureus. 2007; Available from: http://www.idrf.nl/MRSA_werk.pdf. Ac-cessed 18 November 2007.
   Google Scholar